Physicians' Academy for Cardiovascular Education

Association between EPA/AA ratio and plaque characteristics in stable CAD patients on statins

Impact of the eicosapentaenoic acid to arachidonic acid ratio on plaque characteristics in statin-treated patients with coronary artery disease

Literature - Asakura K, Minami Y, Nagata T, et al. - J Clin Lipidol. 2023 Jan-Feb;17(1):189-196. doi: 10.1016/j.jacl.2022.11.011

Introduction and methods


In patients with coronary artery disease (CAD), a low eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratio is associated with subsequent adverse coronary events [1,2], even in those on statin treatment [3]. However, the association of the EPA/AA ratio with coronary plaque characteristics in statin-treated patients with established CAD remains to be elucidated.

Aim of the study

The authors performed a detailed assessment of the characteristics of nonculprit coronary plaques and investigated the association between these characteristics and the EPA/AA ratio in statin-treated patients with CAD.


In this single-center, retrospective, cross-sectional, observational study conducted in Japan, 370 consecutive patients with stable CAD treated with (mostly low- or moderate-intensity) statins who underwent optical coherence tomography (OCT)–guided PCI for a culprit plaque were included. Characteristics of nonculprit plaques within the same coronary artery that were incidentally imaged were analyzed. Serum levels of EPA and AA and were measured within 24 hours prior to the OCT assessment.

Main results


In this Japanese, retrospective, observational study of statin-treated patients with stable CAD, a low EPA/AA ratio (<0.4) was associated with a higher prevalence of vulnerable characteristics of nonculprit coronary plaques as assessed with OCT, such as lipid-richness and macrophage infiltration, even if LDL-c <100 mg/dL.

The authors believe that their results, taken together with the findings of earlier EPA treatment trials, “may imply the adjunctive and synergistic role of EPA, in addition to LDL-c, in the change in morphologies of coronary plaques and subsequent development of clinical events.”


Show references

Find this article online at J Clin Lipidol.

Share this page with your colleagues and friends: